Retrospective analysis of patients with stage IV non-squamous lung cancer with and without TTF-1- and KRAS-G12-mutation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023890

Enrollment

200

Registered

2020-12-17

Start date

2021-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: Using the same 207 patients we will create two arms twice: One with and one without the mutation under research (TTF-1 or KRAS). Arm 1: Patients with the mutation Group 2: Arm 2: Patients wi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: histologically confirmed non-squamous lung cancer stage IV. Patients from 2016-2019 follow up until the end of 2020

Exclusion criteria

Exclusion criteria: missing mutation analysis, other mutations

Design outcomes

Primary

Measure	Time frame
Overall survival, calculated from the dates of histological confirmation until the date of death. We will analyse this date (time to event) using a Kaplan-Meier curve and hazard ratio, mean value and log-rank-test.	—

Secondary

Measure	Time frame
Percentage of patients expressing the mutations and their specific subtype (KRAS-G12D, G12C,...). Correlation between KRAS/TTF-1 and smoking?	—

Countries

Germany

Contacts

Public ContactWolfgang Schütte

Krankenhaus Martha-Maria Halle-Dölau

Innere-Medizin2.Halle@Martha-Maria.de0345-559 1440

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026